Insider Transactions in Q2 2024 at Replimune Group, Inc. (REPL)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
15,881
-11.94%
|
$111,167
$7.5 P/Share
|
|
May 16
2024
|
Colin Love Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
17,615
-2.22%
|
$105,690
$6.47 P/Share
|
|
May 16
2024
|
Andrew Schwendenman Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,298
-5.67%
|
$13,788
$6.47 P/Share
|
|
May 16
2024
|
Christopher Sarchi Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,218
-2.35%
|
$13,308
$6.47 P/Share
|
|
May 16
2024
|
Konstantinos Xynos Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
6,367
-4.57%
|
$38,202
$6.47 P/Share
|
|
May 16
2024
|
Sushil Patel Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
20,194
-8.7%
|
$121,164
$6.47 P/Share
|
|
May 16
2024
|
Robert Coffin Director |
SELL
Open market or private sale
|
Direct |
11,464
-0.63%
|
$68,784
$6.47 P/Share
|
|
May 16
2024
|
Philip Astley Sparke Executive Chairman |
SELL
Open market or private sale
|
Direct |
37,928
-2.49%
|
$227,568
$6.47 P/Share
|
|
Apr 01
2024
|
Andrew Schwendenman Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,775
+30.48%
|
-
|
|
Apr 01
2024
|
Christopher Sarchi Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,225
+19.05%
|
-
|
|
Apr 01
2024
|
Emily Luisa Hill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,665
+19.51%
|
-
|
|
Apr 01
2024
|
Konstantinos Xynos Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,665
+16.06%
|
-
|
|
Apr 01
2024
|
Sushil Patel Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
83,335
+26.41%
|
-
|